drugset / Trial / NCT04338906
Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19
Phase 4
Withdrawn
Heinrich-Heine University, Duesseldorf
Goethe University · collabHospital Schwabing Munich, Germany · collabMissioklinik, Wuerzburg, Germany · collabSt. Georg Hospital Leipzig, Germany · collabUniversitätsklinikum Hamburg-Eppendorf · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Evaluation of the efficacy and safety of hydroxychloroquine - camostat combination therapy in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial Primary Objectives: The primary objective of this study is to demonstrate, that a combination therapy of hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in participants with moderate COVID-19.
Timeline
- Start
- 2020-05
- Primary completion
- 2021-12
- Completion
- 2021-12
Outcome
Outcome not reported
Stopped (Business): “lack of public funding; planned control arm with Hydroxychloroquine treatment showed out as not being standard of care anymore as time evolved.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camostat | Unknown | 400 mg | — |
| Background | Hydroxychloroquine | Small molecule | 200 mg | — |